2,4-Thiazolidinedione,5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (122320-73-4)

Identification
Name:	2,4-Thiazolidinedione,5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-
Synonyms:	5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione;5-[[4-[2-[N-Methyl-N-(2-pyridyl)amino]ethoxy]phenyl]methyl]thiazolidine-2,4-dione;BRL 49653;Rosiglizole;TDZ 01;
CAS:	122320-73-4
Molecular Formula:	C18H19N3O3S
Molecular Weight:	357.43
InChI:	InChI=1/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
Molecular Structure:
Properties
Melting Point:	153-155 C
Density:	1.315g/cm³
Solubility:	In water, 10.45 mg/L at 25 deg C (est)
Appearance:	White to off-white crystalline powder
Specification:	Side-effects and contraindications of Rosiglitazone (CAS NO.122320-73-4) 1. A press release by GlaxoSmithKline in February 2007 noted that there is a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. 2. A meta-analysis reported in May 2007 that the use of rosiglitazone was associated with a significantly increased risk of heart attack. 3. As early as September 2005, both Rosiglitazone and Pioglitazone have been suspected of causing Macular Edema, which causes partial blindness in various spots of the angle of vision.
Color:	Colorless crystals from methanol Solid
Safety Data